XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Frequently asked questions
What sector does XORTX Therapeutics Inc (XRTX) operate in?
XORTX Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is XORTX Therapeutics Inc (XRTX) current stock price?
As of the latest data, XORTX Therapeutics Inc stock price is $1.06, with a previous close of $0.92. XORTX Therapeutics Inc gained $0.14 in the last trading session, representing a 15.2% increase.
What is XORTX Therapeutics Inc (XRTX) current market capitalization?
XORTX Therapeutics Inc market cap is approximately 1.93 million.
What is XORTX Therapeutics Inc (XRTX) Earnings Per Share (EPS)?
The trailing EPS is -$2.54, and the forward EPS is $1.10.
What is XORTX Therapeutics Inc (XRTX) EBITDA?
XORTX Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.67 million.
Does XORTX Therapeutics Inc (XRTX) pay dividends?
No. XORTX Therapeutics Inc does not pay a dividend.
When is XORTX Therapeutics Inc (XRTX) next earnings report?
XORTX Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is XORTX Therapeutics Inc (XRTX) beta (volatility) score?
XORTX Therapeutics Inc has a beta of 0.444, indicating lower volatility than the overall market.
